

Innovative Solutions for NAFLD

By Carrie Decker, ND

COMPLETE REFERENCES

1. Shaw JE, et al. Type 2 diabetes worldwide according to the new classification and criteria. *Diabetes Care*. 2000 Apr;23 Suppl 2:B5-10.
2. Zheng Y, et al. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol*. 2018 Feb;14(2):88-98.
3. Vanni E, et al. From the metabolic syndrome to NAFLD or vice versa? *Dig Liver Dis*. 2010 May;42(5):320-30.
4. Zelman S. The liver in obesity. *AMA Arch Intern Med*. 1952 Aug;90(2):141-56.
5. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc*. 1980 Jul;55(7):434-8.
6. Brunt EM, et al. Nonalcoholic fatty liver disease. *Nature Reviews Disease Primers*. 2015;1:15080.
7. Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Mayo Clinic Proceedings*. 2015;90(9):1233-1246.
8. Cusi K, et al. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. *Diabetes Obes Metab*. 2017 Nov;19(11):1630-4.
9. Silverman JF, et al. Liver pathology in morbidly obese patients with and without diabetes. *Am J Gastroenterol*. 1990 Oct;85(10):1349-55.
10. Clain DJ, Lefkowitz JH. Fatty liver disease in morbid obesity. *Gastroenterol Clin North Am*. 1987 Jun;16(2):239-52.
11. Ali AH, et al. Recent advances in the development of farnesoid X receptor agonists. *Ann Transl Med*. 2015 Jan;3(1):5.
12. Gu M, et al. Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl X receptor. *Front Pharmacol*. 2016 Sep 28;7:345.
13. Traussnigg S, et al. Efficacy and safety of the non-steroidal farnesoid X receptor agonist PX-104 in patients with non-alcoholic fatty liver disease (NAFLD). *Zeitschrift für Gastroenterologie*. 2017 May;55(05):A71.
14. Narasimhan S, et al. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. *Clin Biochem*. 2010 Jul;43(10-11):815-21.
15. Valenzuela A, et al. Selectivity of silymarin on the increase of the GSH content in different tissues of the rat. *Planta Med*. 1989 Oct;55(5):420-2.



16. Zhong S, et al. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: a meta-analysis (PRISMA) of randomized control trials. *Medicine (Baltimore)*. 2017 Dec;96(49):e9061.
17. Hajiaghahmohammadi AA, et al. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. *Hepat Mon*. 2012 Aug;12(8):e6099.
18. Famouri F, et al. The effect of silymarin on non-alcoholic fatty liver disease of children. *J HerbMed Pharmacol*. 2017;6(1):16-20.
19. Zhu X, et al. [The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease](#). *Molecules*. 2016 Oct 14;21(10).
20. Lan J, et al. [Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension](#). *J Ethnopharmacol*. 2015 Feb 23;161:69-81.
21. Sun R, et al. [Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway](#). *Mol Pharmacol*. 2017 Feb;91(2):110-122.
22. Guo T, et al. [Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity](#). *Sci Rep*. 2016 Mar 3;6:22612.
23. Schattenberg JM, et al. [JNK1 but not JNK2 promotes the development of steatohepatitis in mice](#). *Hepatology*. 2006 Jan;43(1):163-72.
24. Ma X, et al. The Pathogenesis of Diabetes Mellitus by Oxidative Stress and Inflammation: Its Inhibition by Berberine. *Front Pharmacol*. 2018 Jul 27;9:782.
25. Kapil S, et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. *J Gastroenterol Hepatol*. 2016 Jan;31(1):213-21.
26. Reilly NR, et al. Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. *J Hepatol*. 2015 Jun;62(6):1405-11.
27. Chao CY, et al. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. *World J Gastroenterol*. 2016 Sep 14;22(34):7727-34.
28. Ilan Y. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. *World J Gastroenterol*. 2012 Jun 7;18(21):2609-18.
29. Miele L, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. *Hepatology*. 2009 Jun;49(6):1877-87.
30. Han J, et al. [Modulating gut microbiota as an anti-diabetic mechanism of berberine](#). *Med Sci Monit*. 2011;17:RA164-7.
31. Gu L, et al. [Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxemia](#). *J Infect Dis*. 2011 Jun 1;203(11):1602-12.
32. Li N, et al. [Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells](#). *Eur J Pharm Sci*. 2010 Apr 16;40(1):1-8.
33. Yan HM, et al. [Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease](#). *PLoS One*. 2015 Aug 7;10(8):e0134172.
34. Cardinali DP, Hardeland R. Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies. *Neuroendocrinology*. 2017;104(4):382-97.

35. Cardinali DP, Vigo DE. Melatonin, mitochondria, and the metabolic syndrome. *Cell Mol Life Sci.* 2017 Nov;74(21):3941-54.
36. Reiter RJ, et al. Melatonin as an antioxidant: under promises but over delivers. *J Pineal Res.* 2016 Oct;61(3):253-78.
37. Cipolla-Neto J, et al. Melatonin, energy metabolism, and obesity: a review. *J Pineal Res.* 2014 May;56(4):371-81.
38. Zanuto R, et al. Melatonin improves insulin sensitivity independently of weight loss in old obese rats. *J Pineal Res.* 2013 Sep;55(2):156-65.
39. Jiménez-Aranda A, et al. Melatonin induces browning of inguinal white adipose tissue in Zucker diabetic fatty rats. *J Pineal Res.* 2013 Nov;55(4):416-23.
40. Szewczyk-Golec K, et al. Melatonin Supplementation Lowers Oxidative Stress and Regulates Adipokines in Obese Patients on a Calorie-Restricted Diet. *Oxid Med Cell Longev.* 2017;2017:8494107.
41. Agahi M, et al. Effect of melatonin in reducing second-generation antipsychotic metabolic effects: A double blind controlled clinical trial. *Diabetes Metab Syndr.* 2018 Jan-Mar;12(1):9-15.
42. Modabbernia A, et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. *J Psychiatr Res.* 2014 Jun;53:133-40.
43. Mostafavi A, et al. Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. *Acta Med Iran.* 2014;52(10):734-9.
44. Mesri Alamdari N, et al. A double-blind, placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women. *Horm Metab Res.* 2015 Jun;47(7):504-8.
45. Mantena SK, et al. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. *Free Radic Biol Med.* 2008 Apr 1;44(7):1259-72.
46. Agil A, et al. Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats. *J Pineal Res.* 2015 Aug;59(1):70-9.
47. Cheshchevik V, et al. Corrections by melatonin of liver mitochondrial disorders under diabetes and acute intoxication in rats. *Cell Biochem Funct.* 2011 Aug;29(6):481-8.
48. Reiter RJ, et al. Mitochondria: Central Organelles for Melatonin's Antioxidant and Anti-Aging Actions. *Molecules.* 2018 Feb 24;23(2).
49. Reiter RJ, et al. Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas. *Cell Mol Life Sci.* 2017 Nov;74(21):3863-81.
50. Gonciarz M, et al. Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin. *J Pineal Res.* 2013 Mar;54(2):154-61.
51. Gonciarz M, et al. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin. *J Physiol Pharmacol.* 2010 Dec;61(6):705-10.
52. Gonciarz M, et al. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. *J Physiol Pharmacol.* 2012 Feb;63(1):35-40.

53. Chojnacki C, et al. The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment. *Biomed Res Int*. 2017;2017:3204504.
54. Zhang JJ, et al. Effects of Melatonin on Liver Injuries and Diseases. *Int J Mol Sci*. 2017 Mar 23;18(4).
55. Zhu Q, et al. Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques. *Sci Rep*. 2018 May 23;8(1):8051.
56. Yoritaka A, et al. Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial. *Mov Disord*. 2013 Jun;28(6):836-9.
57. Matei N, et al. Emerging mechanisms and novel applications of hydrogen gas therapy. *Med Gas Res*. 2018 Sep 25;8(3):98-102.
58. Qian L, et al. Medical Application of Hydrogen in Hematological Diseases. *Oxid Med Cell Longev*. 2019 Nov 28;2019:3917393.
59. Ichihara M, et al. Beneficial biological effects and the underlying mechanisms of molecular hydrogen - comprehensive review of 321 original articles. *Med Gas Res*. 2015 Oct 19;5:12.
60. Kajiyama S, et al. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. *Nutr Res*. 2008 Mar;28(3):137-43.
61. Nakao A, et al. Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome-an open label pilot study. *J Clin Biochem Nutr*. 2010 Mar;46(2):140-9.
62. Lin CP, et al. Anti-oxidant and anti-inflammatory effects of hydrogen-rich water alleviate ethanol-induced fatty liver in mice. *World J Gastroenterol*. 2017 Jul 21;23(27):4920-4934.
63. Zhang JY, et al. Hydrogen-rich water protects against acetaminophen-induced hepatotoxicity in mice. *World J Gastroenterol*. 2015 Apr 14;21(14):4195-209.
64. Kawai D, et al. Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. *Hepatology*. 2012 Sep;56(3):912-21.
65. Jackson K, et al. Effects of alkaline-electrolyzed and hydrogen-rich water, in a high-fat-diet nonalcoholic fatty liver disease mouse model. *World J Gastroenterol*. 2018 Dec 7;24(45):5095-5108.
66. Korovljev D, et al. Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: a randomized controlled pilot trial. *Clin Res Hepatol Gastroenterol*. 2019 Apr 11.
67. El Hadi H, et al. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? *Antioxidants (Basel)*. 2018 Jan 16;7(1).
68. Pervez MA, et al. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease. *Turk J Gastroenterol*. 2018 Mar;29(2):170-176.
69. Parker HM, et al. [Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis](#). *J Hepatol*. 2012;56(4):944-951.
70. Guerrerio AL, et al. [Choline intake in a large cohort of patients with nonalcoholic fatty liver disease](#). *Am J Clin Nutr*. 2012 Apr;95(4):892-900.
71. Ma YY, et al. [Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis](#). *World J Gastroenterol*. 2013 Oct 28;19(40):6911-8.